Makoto Akimoto

2.6k total citations
17 papers, 642 citations indexed

About

Makoto Akimoto is a scholar working on Neurology, Pharmacology and Cardiology and Cardiovascular Medicine. According to data from OpenAlex, Makoto Akimoto has authored 17 papers receiving a total of 642 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Neurology, 5 papers in Pharmacology and 2 papers in Cardiology and Cardiovascular Medicine. Recurrent topics in Makoto Akimoto's work include Amyotrophic Lateral Sclerosis Research (9 papers), Parkinson's Disease Mechanisms and Treatments (5 papers) and Cholinesterase and Neurodegenerative Diseases (4 papers). Makoto Akimoto is often cited by papers focused on Amyotrophic Lateral Sclerosis Research (9 papers), Parkinson's Disease Mechanisms and Treatments (5 papers) and Cholinesterase and Neurodegenerative Diseases (4 papers). Makoto Akimoto collaborates with scholars based in Japan and United States. Makoto Akimoto's co-authors include Kazuoki Kondo, Hiide Yoshino, Shoji Tsuji, Manabu Doyu, Koji Abe, Gen Sobue, Masashi Aoki, Yasuto Itoyama, Chikuma Hamada and Tomotari MITSUOKA and has published in prestigious journals such as Neurology, Phytotherapy Research and Clinical Therapeutics.

In The Last Decade

Makoto Akimoto

17 papers receiving 601 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Makoto Akimoto Japan 7 334 192 171 109 107 17 642
Can Cui China 16 184 0.6× 222 1.2× 84 0.5× 7 0.1× 41 0.4× 48 604
Bahram Bibak Iran 14 39 0.1× 183 1.0× 34 0.2× 26 0.2× 45 0.4× 38 480
Sarah L. Miles United States 14 127 0.4× 308 1.6× 11 0.1× 15 0.1× 52 0.5× 27 723
Vibha Taneja India 12 107 0.3× 356 1.9× 37 0.2× 25 0.2× 57 0.5× 22 624
K.S. Rao Panama 7 67 0.2× 135 0.7× 37 0.2× 12 0.1× 52 0.5× 18 332
Zakieh Keshavarzi Iran 14 65 0.2× 150 0.8× 12 0.1× 10 0.1× 56 0.5× 41 478
Daisaku Yoshihara Japan 8 69 0.2× 150 0.8× 19 0.1× 8 0.1× 29 0.3× 17 378
Michela Rolfo Italy 7 37 0.1× 265 1.4× 49 0.3× 8 0.1× 23 0.2× 10 633
Y. Shukla India 15 55 0.2× 173 0.9× 9 0.1× 52 0.5× 47 0.4× 27 534

Countries citing papers authored by Makoto Akimoto

Since Specialization
Citations

This map shows the geographic impact of Makoto Akimoto's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Makoto Akimoto with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Makoto Akimoto more than expected).

Fields of papers citing papers by Makoto Akimoto

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Makoto Akimoto. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Makoto Akimoto. The network helps show where Makoto Akimoto may publish in the future.

Co-authorship network of co-authors of Makoto Akimoto

This figure shows the co-authorship network connecting the top 25 collaborators of Makoto Akimoto. A scholar is included among the top collaborators of Makoto Akimoto based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Makoto Akimoto. Makoto Akimoto is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

17 of 17 papers shown
1.
Shimizu, H., Yukiko Nishimura, Makoto Akimoto, et al.. (2023). Pharmacokinetics of Edaravone Oral Suspension in Patients With Amyotrophic Lateral Sclerosis. Clinical Therapeutics. 45(12). 1251–1258. 6 indexed citations
2.
Shimizu, H., et al.. (2022). Food Effect Study to Assess the Impact on Edaravone Pharmacokinetic Profiles in Healthy Participants. Clinical Therapeutics. 44(12). 1552–1565. 2 indexed citations
3.
Shimizu, H., Yukiko Nishimura, Hideaki Matsuda, et al.. (2021). Evaluation of Pharmacokinetics, Safety, and Drug‐Drug Interactions of an Oral Suspension of Edaravone in Healthy Adults. Clinical Pharmacology in Drug Development. 10(10). 1174–1187. 25 indexed citations
4.
Nakamaru, Yoshinobu, et al.. (2020). An Open-label, Single-dose Study to Evaluate the Pharmacokinetic Variables of Edaravone in Subjects with Mild, Moderate, or No Renal Impairment. Clinical Therapeutics. 42(9). 1699–1714. 6 indexed citations
5.
6.
Shimizu, H., Shinsuke Inoue, Yoshinobu Nakamaru, et al.. (2020). A Randomized, Single‐Blind, Placebo‐Controlled, 3‐Way Crossover Study to Evaluate the Effect of Therapeutic and Supratherapeutic Doses of Edaravone on QT/QTc Interval in Healthy Subjects. Clinical Pharmacology in Drug Development. 10(1). 46–56. 5 indexed citations
7.
Watanabe, Kazutoshi, et al.. (2017). Edaravone and its clinical development for amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 18(sup1). 5–10. 68 indexed citations
8.
Sakata, Takeshi, Joseph Palumbo, Makoto Akimoto, & Masahiko Tanaka. (2016). A Long-Term Safety and Efficacy Extension Study of Patients Diagnosed with Amyotrophic Lateral Sclerosis (ALS) and Treated with Edaravone (MCI-186) (P3.192). Neurology. 86(16_supplement). 4 indexed citations
9.
Tanaka, Masahiko, Makoto Akimoto, Joseph Palumbo, & Takeshi Sakata. (2016). A Double-Blind, Parallel-Group, Placebo-Controlled, 24-Week, Exploratory Study of Edaravone (MCI-186) for the Treatment of Advanced Amyotrophic Lateral Sclerosis (ALS) (P3.191). Neurology. 86(16_supplement). 5 indexed citations
10.
Palumbo, Joseph, Takeshi Sakata, Masahiko Tanaka, & Makoto Akimoto. (2016). Sustained Efficacy for up to 12 Months in an Active Extension of a Phase III Study of Edaravone (MCI-186) for Treatment of Amyotrophic Lateral Sclerosis (ALS) (P3.190). Neurology. 86(16_supplement). 1 indexed citations
11.
Tanaka, Masahiko, Takeshi Sakata, Joseph Palumbo, & Makoto Akimoto. (2016). A 24-Week, Phase III, Double-Blind, Parallel-Group Study of Edaravone (MCI-186) for Treatment of Amyotrophic Lateral Sclerosis (ALS) (P3.189). Neurology. 86(16_supplement). 14 indexed citations
12.
Abe, Koji, Yasuto Itoyama, Gen Sobue, et al.. (2014). Confirmatory double-blind, parallel-group, placebo-controlled study of efficacy and safety of edaravone (MCI-186) in amyotrophic lateral sclerosis patients. Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. 15(7-8). 610–617. 266 indexed citations
13.
Tanaka, Shigeo, et al.. (1996). Volatile Antiallergic Principles from a Traditional Herbal Prescription of Kampo Medicine. Phytotherapy Research. 10(3). 238–241. 9 indexed citations
14.
Seki, H., et al.. (1994). Effects of Tripalmitin and Safflower Oil on the Content of Short-chain Fatty Acids in the Cecum and on the Fecal Excretion of Lipids in Rats. Bioscience Biotechnology and Biochemistry. 58(7). 1316–1317. 1 indexed citations
15.
Maezaki, Yuji, Keisuke Tsuji, Yasue Nakagawa, et al.. (1993). Hypocholesterolemic Effect of Chitosan in Adult Males. Bioscience Biotechnology and Biochemistry. 57(9). 1439–1444. 187 indexed citations
16.
Tanaka, Shigeo, et al.. (1991). Anti-Allergic Effect of Bryonolic Acid fromLuffa cylindricaCell Suspension Cultures. Planta Medica. 57(6). 527–530. 36 indexed citations
17.
Akimoto, Makoto, et al.. (1986). Effect of excess phosphorus diet of calcium, phosphorus and magnesium metabolism in rats.. The Japanese Journal of Nutrition and Dietetics. 44(2). 79–86. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Can Cui Breakdown of academic impact, for papers by Bahram Bibak Breakdown of academic impact, for papers by Sarah L. Miles Breakdown of academic impact, for papers by Vibha Taneja Breakdown of academic impact, for papers by K.S. Rao Breakdown of academic impact, for papers by Zakieh Keshavarzi Breakdown of academic impact, for papers by Daisaku Yoshihara Breakdown of academic impact, for papers by Michela Rolfo Breakdown of academic impact, for papers by Y. Shukla
Rankless by CCL
2026